January 4, 2010

A new research program called the Medication Exposure in Pregnancy Risk Evaluation will fund research...

January 4, 2010

A subsidiary of a generic drug maker has entered into a new licensing and development...

January 4, 2010

An India drug maker is in generic drug supply talks with two companies, according to...

January 3, 2010

Novartis is looking to purchase the remaining shares in an eye care company....

January 3, 2010

With an eye to the future, Novartis brass envisions a growth arena driven by the...

December 31, 2009

Stymied by weak demand in a recessionary economy, intensifying generic competition, a relative dearth of research-and-development breakthroughs and an ongoing loss of patent protection for some of their biggest-selling pioneering medicines, branded pharmaceutical manufacturers have scrambled over the last three years to restore their once-enviable track record for product innovation and sales growth. And 2009 was no exception.

December 20, 2009

This is further substantiation that the business of over-the-counter medicines, particularly those sold in the...

December 3, 2009

The digestives aisle will be altogether crowded come early 2010, especially with two new proton-pump...

October 18, 2009

What’s really intriguing behind the return of a consumer division to Pfizer is the fact...

September 10, 2009

A murky and long-unresolved dispute over the prices pharmaceutical wholesalers pay for the drugs they...

August 30, 2009

Over-the-counter medicines save healthcare dollars. It’s certainly a value that consumers are taking advantage of...

August 23, 2009

This agency pulls no punches. The merest blip of a post-marketing serious adverse event report,...

August 20, 2009

Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody”...

July 5, 2009

This battle was supposed to be over by now....

June 28, 2009

There was speculation in January that Schering-Plough’s switch application around the proton-pump inhibitor Zegerid was...

April 9, 2009

A lot of news has been coming from the Food and Drug Administration lately. And...

March 12, 2009

The long-awaited breakthrough for follow-on biologics may be close at hand....

March 12, 2009

The last few weeks have seen a lot of acquisition activity among large pharmaceutical companies....

February 26, 2009

The Pharmaceutical Research and Manufacturers of America released a report Thursday showing a record...

February 19, 2009

In dismal economic times, lower-cost product alternatives that save consumers money are supposed to thrive, or at least hold their own. But in the midst of a global financial meltdown, even the market for generic drugs is faltering. The worldwide sales growth rate of me-too medicines slowed to a crawl in the 12 months ended September 2008, rising a weak 3.6% over the previous 12-month period, IMS Health reported.

January 29, 2009

The deal gives a great deal of added heft to Pfizer’s pharmaceutical division — the...

January 11, 2009

Par Pharmaceutical Cos. had total sales of $291.9 million and $26.3 million in profit for...

January 4, 2009

If current trends in pharmaceutical sales are any indication, retail pharmacy leaders may have to look beyond the prescription department for big gains in store revenues this year. Hammered by a lack of new breakthroughs in research and development, tougher oversight at the Food and Drug Administration, generic competition and a worldwide economy in free fall, the U.S. pharmaceutical market is mired in an era of stagnant sales and declining expectations. And the outlook for an uptick in innovative new therapies from drug makers remains at historically low levels, according to industry experts.

November 10, 2008

The situation is like having plans to bake a loaf of bread for dinner, but discovering at 5 p.m. that the flour is running low, and there is little time to go to the supermarket to buy more. Generic drug makers depend on a steady supply of expiring patents coming from large pharmaceutical companies for their business. In recent years, a whole slew of blockbuster drugs have come off patent, allowing generic drug makers to lap up the drug compounds. Over the next several years, however, the supply of expiring patents will begin to run dry. Between this year and 2016, $131 billion worth of drugs will come off patent, followed by a long decline often called the patent cliff. Facing this precipice, generic drug companies will have to adapt as the market becomes increasingly commoditized.